

GHOSN Marwan

Beirut Central District, Allenby Street, Marfaa 27 Building, 1st Floor

P.O. Box: 166484, Beirut, Lebanon

Tel : +961 1 970220 or +961 1 987220

Mobile : +961 3 226 842

e-Mail : marwan.ghosn@usj.edu.lb; marwan.ghosn@cmc.com.lb; marwanghosnmd@yahoo.com; marwan.ghosn@cmcdubai.ae

Personal Data

Nationality : Lebanese & French
Date of birth : February 10, 1959
Place of Birth : Zouk-Mosbeh, Kesrouane, Lebanon
Sex : Male
Status : Married, 2 children

Languages & Computer Skills

Arabic : Native language.
French : Fluently written and spoken
English : Fluently written and spoken

Secondary School

- 1977 : Lebanese Bacallaureate Diploma
- 1976: Diploma of Graduate in the Secondary Bacallaureate (Diplôme de Bachelier de l'Enseignement du Second Degré), Collège des Frères Passy Buzenval, Rueil Malmaison, France (www.passy-buzenval.com)

Higher Education and Post-Graduate

- **University Diploma**
 - 1983: State Diploma of Doctor in Medicine (Diplôme d'Etat de Docteur en Médecine) Republic of France, Ministry of National Education, France.
 - 1983: Diploma of Doctor in Medicine (Diplôme de Docteur en Medecine), Saint Joseph University, Faculty of Medicine, Beirut, Lebanon.
 - 1983: Certificate "Educational Commission for Foreign Medical Graduates" E.C.F.M.G., U.S.A.
- **Post-Graduates Certificates and Diplomas**
 - 1998: Clinical Exchange Program
The University of Texas, MD Anderson Cancer Center, Houston, Texas
Program sponsor: Robert BENJAMIN, M.D. and Moshe TALPAZ, M.D.

- 1995: Certificate “Introduction to Cancer Epidemiology with Emphasis on Cancer Control”
An International Course, World Health Organization, International Agency for Research on Cancer (IARC), Amman, Jordan.
- 1995: First Course of Practical Blood Stem Transplantation
Herlev University of Copenhagen
Coordinator: Professors Niels Ebbe HANSEN and Hans JOHNSEN
- 1993: Course/Seminar “Postgraduate Athens Lymphoma Course”
European School of Oncology, Athens, Greece
Coordinators: Professors G.A. PANGALIS and A. POLLIACK
- 1988: Certificate of Higher Studies of Human Biology in General and Experimental Oncology (Certificat d’Etudes Supérieures de Biologie Humaine, de Cancérologie Générale et Expérimentale)
University of Paris-South (Paris XI), U.E.R. Kremlin-Bicêtre, France.
Coordinator: Professor Georges MATHE.
- 1987: Advanced Course of Pediatric Oncology (Cours d’Oncologie Pédiatrique)
Institut Gustave - Roussy, Villejuif, France.
Coordinator: Professor Jean LEMERLE
- 1987: Lebanese Board in Medical Oncology (Post Graduate Speciality Diploma)
Saint Joseph University, Faculty of Medicine, Beirut, Lebanon.
Coordinator: Professor Nagib TALEB
- 1986: Advanced Course of Chemotherapy (Cours de l’Enseignement de Chimiothérapie),
Institut Gustave - Roussy, Villejuif, France.
Coordinator: Professor Maurice TUBIANA
- 1985: Certificate in Clinical Oncology (Unité de Valeur de Carcinologie Clinique),
University of Paris-South (Paris XI), U.E.R. Kremlin-Bicêtre, France.
Coordinator: Professor Maurice TUBIANA
- **Management and Health Economics Diplomas**
 - 2006: Specialized Diploma in Hospital and Health Management (Diplôme Spécialisé Management de l’Hôpital et de la Santé).
Superior School of Business (Ecole Supérieure des Affaires - ESA), Beirut, Lebanon
 - 2007: Inter-University Diploma in Economic and Social Sciences of Health (Diplôme Inter Universitaire Sciences Economiques et Sociales de la Santé), Session 2006.
University of Paris 7 Denis Diderot, UFR Lariboisière Saint Louis, Paris, France
 - 2008: Master in Hospital and Health Management.
University of Paris 7 Denis Diderot, UFR Lariboisière Saint Louis, Paris, France
 - 2008: Master in Hospital and Health Management (Diplôme Spécialisé Management de l’Hôpital et de la Santé).
Superior School of Business (Ecole Supérieure des Affaires - ESA), Beirut, Lebanon

▪ **Practice Licenses**

- 2006 - 2008: Professional license to practice as Medical Specialist with the Specialty of Medical Oncology in Dubai Healthcare City.
- 2007: Professional license to practice as Medical Specialist with the Specialty of Medical Oncology in Dubai, Government of Dubai, Dubai, UAE.
- 1988: License to hold a title of Specialist in Medical Oncology, Ministry of Public Health, Republic of Lebanon
- 1983: License for practicing Medicine in the Lebanese Country, Ministry of Public Health, Republic of Lebanon

▪ **International Certification**

- 2012: European Recertification on Medical Oncology, European Society for Medical Oncology (valid till 2016)
- 2001: European Recertification on Medical Oncology, European Society for Medical Oncology (valid till 2012)
- 1994: European Certification on Medical Oncology, European Society for Medical Oncology

Graduate and Post-Graduate Hospital Training

▪ **Graduate Hospital Training :**

- July 1981 – June 1982: Intern at the Departments of Internal Medicine, Surgery, Obstetrics, Gynecology and Pediatrics, Hayek Hospital, Beirut, Lebanon
- July 1982 – June 1983: Intern at the Departments of Internal Medicine, Surgery, Intensive Care Unit and Emergency, Hôtel Dieu de France Hospital, Beirut, Lebanon.

▪ **Post-Graduate Hospital Training :**

- July 1983 – September 1984: Fellow in the Hematology - Oncology at the Department, Hôtel-Dieu de France University Hospital, Beirut, Lebanon
Chairman: Professor Nagib TALEB.
- October 1984 - September 1985: Fellow in Medical Oncology at the Department of Solid Tumors, Institute Gustave-Roussy, Villejuif, France
Chairman: Professor Jean-Pierre DROZ.
- October 1985 – June 1986: Fellow in Hematology at the Department of Hematology, Institute Gustave-Roussy, Villejuif, France
Chairman: Professor Marcel HAYAT.
- October 1985 – June 1986: Training in the Department of “Applied Statistics to Clinical Research”, Institute Gustave-Roussy, Villejuif, France
Chairman: Professor Helene-Sancho GARNIER

- July 1986 – September 1986: Assistant (Consultant) at the Department of Hematology, Institute Gustave-Roussy, Villejuif, France; Paris XI University, U.E.R. Kremlin-Bicêtre
Chairman: Professor Marcel HAYAT
- October 1986 - September 1987: Assistant (Consultant) at the Department of Solid Tumors, Institute Gustave-Roussy, Villejuif, France; Paris XI University, U.E.R. Kremlin-Bicêtre
Chairman: Professor Jean - Pierre DROZ.

Clinical Experience

- September 1987 – October 1988: Practitioner / Consultant (Praticien Attaché), Department of Hematology-Oncology, Hôtel-Dieu de France University Hospital, Beirut, Lebanon
- November 1988 – February 1991: Full time Practitioner / Consultant (Praticien à temps plein), Department of Hematology-Oncology, Hôtel-Dieu de France University Hospital, Beirut, Lebanon
- March 1991 – March 1995: Chairman, Department of Hematology-Oncology, Hôtel-Dieu de France University Hospital, Beirut, Lebanon
- April 1995 – January 1999: Full time Practitioner / Consultant (Praticien à temps plein), Department of Hematology-Oncology, Hôtel-Dieu de France University Hospital, Beirut, Lebanon
- February 1999 – February 2007: Chairman, Department of Hematology-Oncology, Hôtel-Dieu de France University Hospital, Beirut, Lebanon.
- March 2007 - currently: Part Time Practitioner / Consultant, Department of Hematology-Oncology, Hôtel-Dieu de France University Hospital, Beirut, Lebanon.
- March 2007 – currently: Chairman of Hematology-Oncology Division at Clemenceau Medical Center, affiliated with Johns Hopkins International, Beirut – Lebanon.
- October 2008 – currently: Cancer Center Director at Clemenceau Medical Center, affiliated with Johns Hopkins International, Beirut – Lebanon.
- August 2020 – currently: International Visiting Medical Oncologist, Clemenceau Medical Center, Dubai, UAE.

Academic Experience

- October 1987- September 1990: Appointed to teach / Lecturer in Hematology - Oncology (Chargé d'Enseignement), Saint Joseph University, Faculty of Medicine, Department of Hematology and Oncology, Beirut, Lebanon
- October 1990 – September 1997: Assistant Professor (Professeur Adjoint), Saint Joseph University, Faculty of Medicine, Department of Medicine / Hematology and Oncology, Beirut, Lebanon.
- October 1997 – November 2004: Associate Professor (Professeur Associé), Saint Joseph University, School of Medicine, Department of Medicine /Hematology and Oncology, Beirut, Lebanon
- December 2004 - October 2005:

- Professor, Department of Medicine / Oncology
Saint Joseph University, Faculty of Medicine, Beirut, Lebanon
- Professor and Chairman Department of Medicine / Hematology
Saint Joseph University, Faculty of Medicine, Beirut, Lebanon
- December 2004 – Currently: Chairman, Hematology Department, Saint Joseph University, School of Medicine, Beirut, Lebanon
- October 2005 – Currently: Chairman, Oncology Department, Saint Joseph University, Faculty of Medicine, Beirut, Lebanon
- December 2009 – 2012: Chairman, Public Health and Health Management Department, Saint-Joseph University, Faculty of Medicine, Beirut – Lebanon.

University Teaching Courses

- Saint-Joseph University, Faculty of Medicine, Beirut, Lebanon
 - Since 1987: Certificate of Therapeutic, Doctorate Degree in Medicine Program
 - Since 1987: Certificate of Oncology, Master Degree in Medicine Program
 - Since 1987: Certificate of Hematology, Master Degree in Medicine Program
 - Since 2009: Epidemiology, Clinical Research, Quality and Health Management, Master Degree in Medicine Program
- Saint-Joseph University, Faculty of Nursing, Beirut, Lebanon
 - 1988 – 2000: Hematology and Oncology
 - 2005 - 2006: Oncology, Master in Oncology Nursing University Diploma
- Saint-Joseph University, Faculty of Pharmacy, Beirut, Lebanon
 - 1996 – 2001: Course in Clinical Research, Master Degree
- Saint-Joseph University, University for All (Université Pour Tous), Beirut, Lebanon
 - 2004 – 2005: Cancer Courses – Open courses
- Higher School of Business (ESA), Beirut - Lebanon, in association with Paris VII University, Paris – France
 - Since 2007: Course / Workshop on Risk Management and Patient Safety - Master in Hospital and Health Management
- Lebanese American University, Beirut, Lebanon
 - Dec 2009: Introduction to Oncology, Undergraduate course, Medicine Program

Medical Societies Affiliations

- **Lebanese**
 - **Lebanese Society of Quality and Safety in Health Care** 2012-2015: Member of the Board of Administration, currently Active Member
 - **Lebanese Cancer Society**

1987 - 1991 Active Member
1992 - 2004 Member of the Board of administration
1992 - 1993 General Secretary
1994 - 1999 Treasurer
2000 - current Active Member

- **Lebanese Society for Medical Oncology**

1994 - 2002 Active Member
2002 - 2003 Vice President
2004 - 2005 President
2006 - current Active Member

- **National Cancer Association** 1995 - 2000: Active Member

- **Lebanese Epidemiological Association**

1994 - 2005 Active Member
2005 - 2007 Member of the Board of Administration

- **International**

- American Society of Clinical Oncology (ASCO), Active Member, Since 1998
- The American Society of Hematology (ASH), International Member, Since 2005
- American Association for Cancer Research, Inc. (AACR), Corresponding Member, Since 1993
- The European Society for Medical Oncology (ESMO), Active Member, Since 1993
- International Association for the study of pain (IASP), Member, Since 2004
- International Society of Geriatric Oncology (SIOG), Member, Since 2004
- The International Society of Hematology (ISH), Member, Since 2000
- International Association for the Study of Lung cancer (IASLC), Active Member, Since 2000
- European Hematology Association (EHA), Active Member, Since 1998
- International Epidemiological Association (IEA), Since 1997
- Multinational Association of Supportive Care in Cancer (MASCC), Active Member, Since 1992
- French Cancer Society (SFC), Active Member, Since 2015
- Arab Medical Association Against Cancer, Member Board the Board of Administration since 2007
- Mediterranean Francophone Cancer Society (SMFC), France, Member Board of Administration since 2012
- Francophone d'Oncologie Medicale (FOM), France, Member Executive Committee since 2009

Medical/Hospital/National/Journal Nominations

- 2012-currently: Member of the Medical Board at Clemenceau Medical Center (CMC) affiliated with Johns Hopkins International, Beirut, Lebanon
- 2012- currently: Member of the Medical Quality committee at Clemenceau Medical Center (CMC) affiliated with Johns Hopkins International, Beirut, Lebanon
- 2012- currently: Chairman of the cancer committee at Clemenceau Medical Center (CMC) affiliated with Johns Hopkins International, Beirut, Lebanon
- April 2007 - currently: Member of the Pharmacy and Therapeutics Committee at Clemenceau Medical Center (CMC) affiliated with Johns Hopkins International, Beirut, Lebanon.
- April 2007 - currently: Member of the Safety and Risk Management Committee at Clemenceau Medical Center (CMC) affiliated with Johns Hopkins International, Beirut, Lebanon
- May 2005 and July 1995: Nominated in the National Commission of Diagnosis and Treatment of Cancers, Ministry of Public Health, Beirut, Lebanon
- May 2005: New Nomination as President of the Lebanese Society of Medical Oncology in the Commission of the National Register of Cancer in Lebanon
- 2004 - 2010: Editor-in-Chief, Cancer Letter, The official Journal of the Lebanese Cancer Society
- 2000 - 2003: Member of the Medical Council Board (Conseil Medical) at Hotel-Dieu de France University Hospital (HDF), Saint Joseph University, Beirut, Lebanon
- 2002 - 2012: Medical Advisory Board, Annual Breast Cancer Awareness Campaign, Hoffman-La Roche, Ministry of Public Health, World Health Organization, Lebanon
- 1998 - 2006: Board of Directors, Saint-Joseph University, Faculty of Nursing, Beirut, Lebanon
- 1994 -1998: International Associate Editor Board of the « Bulletin de Cancer », Journal of the French Society of Cancer, France
- 2007 - currently: Editor-in-Chief of the Pan Arab Journal of Oncology (PAJO), the official publication of the Arab Medical Association Against Cancer (AMAAC)
- 1991 -1994: Ethical Committee, Hôtel-Dieu de France, University Hospital (HDF), Saint Joseph University, Beirut, Lebanon
- July 1995: Nominated in the National Commission of the National Register of Cancer, Ministry of Health, Beirut, Lebanon.
- 1993 -1999: Member of the Editorial Board of the “Lebanese Medical Journal”, The official Journal of the Lebanese Order of Physicians, Beirut, Lebanon
- 1991-2003: Pharmacology Board, Hôtel-Dieu de France University Hospital (HDF), Saint Joseph University, Beirut, Lebanon.

Special Nomination and Awards

Decoration by The Lebanese Order of Physicians: May 2004
CNRS-L Eight Annual Research Excellence Award: 2018

Special Post Graduate Grant

Grant from the Association for Cancer Research (Association pour la Recherche sur le Cancer - ARC), Ville-Juif, France for the period between October 1984 till September 1985.

Health Economics and Management Activities

Hospital Management

1. Quality Medical Director

- Hotel Dieu de France University Hospital 2012 - 2013

2. Member of quality and Management Committees

- a) Patient Safety committee CMC till currently
- b) Quality Committee CMC till currently
- c) Hospital Medical Board committee CMC till currently
- d) Member of « Commissions Qualité Sécurité et Environnement » of Hôtel Dieu de France Hospital, 2015-currently
- e) Pharmacy committee Clemenceau Medical Center previously
- f) Pharmacy committee Hotel Dieu de France University Hospital previously
- g) Ethical committee Hotel Dieu de France University Hospital previously

Research Activity

- 1984 / Thesis / Contribution à l'étude du Tamoxifen comme traitement de première ligne dans les métastases du cancer du sein (Contribution to the study of Tamoxifen in the first line treatment of metastatic breast cancer) / Saint Joseph University, School of Medicine, Beirut, Lebanon
- 1987 / Thesis / Aide informatique à la prescription et à l'administration de la chimiothérapie (Informatics help in the prescription of Chemotherapy) / UER Kremlin Bicêtre, Paris-Sud University, France.

Publications

Articles

1. Irreversible encephalopathy with ifosfamide/mesna.

Salloum E, Flamant F, **Ghosn M**, Taleb N, Akatchereian C. J Clin Oncol. 1987 Aug;5(8):1303-4.

2. Locoregional chemotherapy of hepatic metastases of colorectal cancer.

Rougier P, Lasser P, Droz JP, Elias D, **Ghosn M**, Ducreux M, Lumbroso J, Sidibe S. Ann Gastroenterol Hepatol (Paris). 1987 Nov;23(6):315-9. French.

3. **Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.**
De Forges A, Droz JP, **Ghosn M**, Theodore C.
Cancer Treat Rep. 1987 Nov;71(11):1103.
4. **Ifosfamide/mesna related encephalopathy ; a case report with a possible role of phenobarbital in enhancing neurotoxicity.**
Ghosn M, Carde P, Leclercq B, Flamant F, Friedman S, Droz JP, Hayat M.
Bull Cancer. 1988;75(4):391-2.
5. **Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis.**
de Forges A, Rey A, Klink M, **Ghosn M**, Kramar A, Droz JP.
Semin Surg Oncol. 1988;4(3):149-54.
6. **Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy.**
Droz JP, Theodore C, **Ghosn M**, Lupera H, Piot G, De Forges A, Klink M, Rouesse J, Amiel JL.
Semin Surg Oncol. 1988;4(2):97-9.
7. **Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma.**
Piot G, Droz JP, Theodore C, **Ghosn M**, Rouëssé J, Amiel JL.
Oncology. 1988;45(5):371-2.
8. **Vulvar pruritus after high-dose dexamethasone.**
Taleb N, Geahchan N, **Ghosn M**, Brihi E, Sacre P.
Eur J Cancer Clin Oncol. 1988 Mar;24(3):495.
9. **Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.**
Ghosn M, Droz JP, Theodore C, Pico JL, Baume D, Spielmann M, Ostronoff M, Moran A, Salloum E, Kramar A, et al.
Cancer. 1988 Jul 1;62(1):24-7.
10. **Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis.**
Droz JP, Kramar A, **Ghosn M**, Piot G, Rey A, Theodore C, Wibault P, Court BH, Perrin JL, Travagli JP, et al.
Cancer. 1988 Aug 1;62(3):564-8.
11. **Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin.**
Rougier P, Lasser P, Elias D, **Ghosn M**, Ducreux M, Lumbroso J, Sidibe S, Droz JP.
Sel Cancer Ther. 1989;5(1):47-54.
12. **Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumors.**
Droz JP, Ribrag V, **Ghosn M**, Guimares J, Theodore C, Azab M, Ostronoff M, Mahjoubi M, Moran A, Pico J, et al.
Prog Clin Biol Res. 1989;303:739-47.
13. **A phase III trial comparing the antiemetic activity of tetracosactide with dexamethasone in combination with metoclopramide, diphenhydramine and clorazepate during chemotherapy including cisplatin.**
Culine S, Azab M, Pietri F, **Ghosn M**, Ben Amor B, Lupera H, Theodore C, Renaux J, Droz JP.
Bull Cancer. 1989;76(6):583-9. French.
14. **Very late recurrence of childhood acute lymphoblastic leukemia treated with chemoimmunotherapy: a report of three cases occurring 19, 11, and 9 years after discontinuation of chemotherapy.**
Salloum E, Pico JL, Herait P, Bayle C, **Ghosn M**, Moran A, Friedman S, Hayat M.

- 15. Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer.**
Lupera H, Theodore C, **Ghosn M**, Court BH, Wibault P, Droz JP.
Urology. 1989 Nov;34(5):281-3.
- 16. Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer.**
Mahjoubi M, Azab M, **Ghosn M**, Theodore C, Droz JP.
Cancer Invest. 1990;8(5):477-81.
- 17. Inappropriate antidiuretic hormone secretion induced by ifosfamide.**
Culine S, Ghosn M, Droz JP.
Eur J Cancer. 1990;26(8):922.
- 18. Value of high-dose chemotherapy followed by bone marrow autograft in non-seminomatous germinal tumor with poor prognosis. Results of the combination of cisplatin, etoposide and cyclophosphamide (PEC protocol).**
Baume D, Pico JL, Droz JP, Ostronoff M, Azab M, Gilles E, **Ghosn M**, Salloum E, Gouyette A, Beaujean F, et al.
Bull Cancer. 1990;77(2):169-80. French.
- 19. Sarcoidosis and testicular germ cell tumor. Case report.**
Droz JP, Ruffie P, Piot G, **Ghosn M**, Caillaud JM, Elias D, Perrin JL, Levasseur P.
Scand J Urol Nephrol. 1990;24(3):171-3. Review.
- 20. Cancer of the bladder after treatment with cyclophosphamide. Apropos of a case and a review of the literature.**
Lupera H, Droz JP, Culine S, Perrin JL, Court BH, **Ghosn M**, Hayat M.
J Urol (Paris). 1990;96(1):48-52. Review. French.
- 21. Trial of premedication with lorazepam for the prevention of emetic effects of cisplatin.**
Ghosn M, Ha MC, Pietri F, Garcin C, Théodore C, Droz JP.
Bull Cancer. 1990;77(7):695-6. French.
- 22. Phase II trial of pre- and postoperative cisplatin, methotrexate and vinblastine in infiltrating bladder cancer: a three year experience.**
Droz JP, Azab MB, Theodore C, **Ghosn M**, Ostronoff M, Boutan-Laroze A, Court BH, Perrin JL, Travagli JP, Wibault P.
Prog Clin Biol Res. 1990;353:137-42.
- 23. Chemotherapy in advanced transitional cell carcinoma of the urinary tract. Phase II trial of a combination of doxorubicin and cisplatin.**
Ribrag V, Ghnassia M, Théodore C, **Ghosn M**, Piot G, Beurton D, Cukier J, Droz JP.
J Urol (Paris). 1990;96(7):373-4. French.
- 24. Phase II trial of methyl-gag and melphalan in metastatic adult renal cell carcinoma.**
Guimaraes JL, **Ghosn M**, Ostronoff M, Azab M, Theodore C, Droz JP.
Cancer Invest. 1990;8(6):623-4.
- 25. Chemotherapeutic intensification in germ cell tumors.**
Droz JP, Pico JL, **Ghosn M**, Ostronoff M, Azab M, Theodore C, Hayat M.
Bull Cancer. 1990;77(4):349-54. French.
- 26. Salvage chemotherapy of non-seminomatous germ cell tumors. Phase II trial of a combination of etoposide, ifosfamide and high-dose cisplatin.**

Ribrag V, Droz JP, Bouleuc C, Theodore C, **Ghosn M**, Pico JL, Azab M, Ostronoff M, Hayat M.
Presse Med. 1990 Jul 7-14;19(27):1263-6. French.

- 27. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy.**
Droz JP, Schlumberger M, Rougier P, **Ghosn M**, Gardet P, Parmentier C.
Tumori. 1990 Oct 31;76(5):480-3.
- 28. Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer.**
Droz JP, Pico JL, **Ghosn M**, Gouyette A, Baume D, Piot G, Ostronoff M, Theodore C, Beaujean F, Hayat M.
Eur J Cancer. 1991;27(7):831-5.
- 29. Hypothalamo-hypophyseal and gastric metastasis of a breast neoplasm. Clinical case and a review of the literature.**
Ghosn M, Ghayad E, Biagini J, Abi Gerges D.
Bull Cancer. 1991 Nov;78(11):1071-3. French.
- 30. The cancer registry at the Hôtel Dieu de France Hospital.**
Ghosn M, Tannous R, Gedeon E.
J Med Liban. 1992;40(1):4-10. French.
- 31. The use of antiemetics in cancer chemotherapy.**
Ghosn M, Droz JP.
J Med Liban. 1992;40(2):106-7. French.
- 32. Therapeutic problem posed by Gardner's syndrome, report of a Lebanese family.**
Biagini J, Sayegh R, **Ghosn M**.
J Med Liban. 1992;40(2):93-5. French.
- 33. Handling of antineoplastic products and nurses' knowledge.**
Habib C, Karam S, Khaled H, Rustom R, Gueutcherian Y, Akatcherian R, **Ghosn M**.
J Med Liban. 1992;40(4):182-6. French.
- 34. Primary breast lymphoma. A case report.**
Azouri J, Afif N, **Ghosn M**, Nader N, Bou Saba C.
J Med Liban. 1992;40(4):202-6. Review. French.
- 35. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors.**
Droz JP, Pico JL, **Ghosn M**, Kramar A, Rey A, Ostronoff M, Baume D.
Bull Cancer. 1992;79(5):497-507.
- 36. Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma.**
Rougier P, Ammarguella H, **Ghosn M**, Piot G, Benhamed M, Tigaud JM, Laplaige P, Theodore C, Kac J, Goldberg J, et al.
Oncology. 1992;49(1):35-9.
- 37. Phase II trial of pirarubicin in the treatment of advanced bladder cancer.**
Mahjoubi M, Kattan J, **Ghosn M**, Droz JP, Philippot I, Herait P.
Invest New Drugs. 1992 Nov;10(4):317-21.
- 38. Cancer pain: pharmacological management (Part Two).**
Ghosn M, Gannage M.

J Med Liban. 1993;41(4):244-8. Review.

39. Cancer pain: pharmacological management (2).

Ghosn M, Gannage M.

J Med Liban. 1993;41(3):174-6.

40. Infections in cancer patients with granulocytopenia. Retrospective studies of 59 febrile episodes with hospitalization.

Ghosn M, Dagher E, Nasr F, Chahine G, Taleb N, Nasnas R, Ghayad E.

J Med Liban. 1994;42(3):117-22. French.

41. Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases.

Moran-Ribon A, Droz JP, Kattan J, Leclercq B, **Ghosn M**, Couanet D, Ostronoff M, Culine S, Misset B, Escudier B, et al. Support Care Cancer. 1994 Jul;2(4):253-8.

42. Gastric metastases of breast cancer.

Abboud B, Sayegh R, Chahine G, **Ghosn M**, Ingea H, Biajini J, Farah P.

Presse Med. 1994 Dec 3;23(38):1758-9. French.

43. Cancer in the elderly. A special and unique entity.

Kattan J, **Ghosn M**.

J Med Liban. 1997;45(3):172-3. Review.

44. Chemoprevention of breast cancer. Impact of a new therapeutic strategy.

Kattan J, **Ghosn M**.

J Med Liban. 1999 Sep-Oct;47(5):284-5. French.

45. Health status of Lebanese ophthalmologists.

Mansour AM, Shoughari AT, Ghazi NG, Mokdad F, **Ghosn M**.

Clin Exp Ophthalmol. 2002 Feb;30(1):60-1.

46. A case of pancreatitis associated with all-trans-retinoic acid therapy in acute promyelocytic leukemia.

Abou Chacra L, **Ghosn M**, Ghayad E, Honein K.

Hematol J. 2001;2(6):406-7.

47. Mesothelioma--asbestos in Lebanon: a problem to be considered.

Kattan J, Faraj H, **Ghosn M**, Chahine G, Assaf E, Abadjian G, Khoury F.

J Med Liban. 2001 Nov-Dec;49(6):333-7. French.

48. Vertebral actinomycosis: case report and review of the literature.

El Murr T, Tohme A, Farah E, Abadjian G, **Ghosn M**, Ghayad E.

J Med Liban. 2001 Nov-Dec;49(6):355-8. Review. French.

49. Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer.

Nasr FL, Chahine GY, Kattan JG, Farhat FS, Mokaddem WT, Tuani EA, Dagher JE, **Ghosn M**.

Clin Breast Cancer. 2004 Jun;5(2):117-22; discussion 123-4.

50. Granulocytic sarcoma with spinal cord compression in chronic myelogenous leukemia: a case report.

Chalhoub-Hachem BR, Kattan JG, **Ghosn M**, Abadjian GA, Okais NM.

J Med Liban. 2003 Apr-Jun;51(2):117-9.

- 51. Outcome of cancer patients admitted to the intensive care unit (ICU).**
Ghosn M, Kanso C, Kattan J, Chahine G, Tueini E, Nasser E, Yazbeck P.
J Med Liban. 2002 Jul-Aug;50(4):132-6.
- 52. Peritoneal pseudomyxoma: two case reports and review of the literature.**
El Murr T, Tohme A, Ghosn M, Tohme C, Ghayad E.
J Med Liban. 2002 Jul-Aug;50(4):187-90. Review. French.
- 53. Cancer incidence in postwar Lebanon: findings from the first national population-based registry, 1998.**
Shamseddine A, Sibai AM, Gehchan N, Rahal B, El-Saghir N, Ghosn M, Aftimos G, Chamsuddine N, Seoud M;
Lebanese Cancer Epidemiology Group.
Ann Epidemiol. 2004 Oct;14(9):663-8.
- 54. A five-year experience in conformational radiotherapy in the treatment of prostate cancer. Evaluation of acute toxicity in 131 patients.**
Nasr E, Merhej S, Nehme Nasr D, Fares G, Moukarzel M, Chalouhi E, Bulbul M, Sarkis P, Nemr E, Jabbour M, Khoury R, Ghazale G, Chehade G, Ghosn M, Chahine G, Abillamah A.
Prog Urol. 2005 Feb;15(1):36-9. French.
- 55. Current strategies in the treatment of metastatic hormone-refractory prostate cancer.**
Ghosn M, Kattan J, Younes F.
Tunis Med. 2005 Dec;83 Suppl 12:74.
- 56. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients.**
Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J.
Anticancer Res. 2006 May-Jun;26(3B):2451-6.
- 57. Depth-resolved monitoring of glucose diffusion in tissues by using optical coherence tomography.**
Ghosn M, Tuchin VV, Larin KV.
Opt Lett. 2006 Aug 1;31(15):2314-6.
- 58. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.**
Ghosn M, Farhat F, Kattan J, Younes F, Moukadem W, Nasr F, Chahine G.
Am J Clin Oncol. 2007 Feb;30(1):15-20.
- 59. Nondestructive quantification of analyte diffusion in cornea and sclera using optical coherence tomography.**
Ghosn M, Tuchin VV, Larin KV.
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2726-33.
- 60. Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial.**
Ghosn M, Kattan J, Farhat F, Younes F, Nasr F, Moukadem W, Gasmi J, Chahine G; Cancer Research Group/Collaborative Group (CRG/CG), Beirut-Lebanon.
Cancer Chemother Pharmacol. 2008 Jun;62(1):11-8. Epub 2007 Aug 24.
- 61. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).**
Kattan JG, Farhat FS, Chahine GY, Nasr FL, Moukadem WT, Younes FC, Yazbeck NJ, Ghosn M; Cancer Research Group.
Invest New Drugs. 2008 Feb;26(1):75-9. Epub 2007 Sep 6.
- 62. Internal medicine residents' perception of nursing home demographics and regulations: a pilot study.**
Lester PE, Doubrovskaja M, Ghosn M, Gomolin IH.

- 63. Permeability of hyperosmotic agent in normal and atherosclerotic vascular tissues.**
Ghosn M, Carbajal EF, Befrui NA, Tellez A, Granada JF, Larin KV.
J Biomed Opt. 2008 Jan-Feb;13(1):010505. doi: 10.1117/1.2870153.
- 64. Differential permeability rate and percent clearing of glucose in different regions in rabbit sclera.**
Ghosn M, Carbajal EF, Befrui NA, Tuchin VV, Larin KV.
J Biomed Opt. 2008 Mar-Apr;13(2):021110. doi: 10.1117/1.2907699.
- 65. Value of US imaging following mastectomy.**
Kanso H, Kazzi H, Menassa-Moussa L, Abi Khalil S, Ghosn M, Chahine G, Tohmé C, Aoun N, Ghossain M.
J Radiol. 2008 Sep;89(9 Pt 1):1077-80. French.
- 66. Live imaging of blood flow in mammalian embryos using Doppler swept-source optical coherence tomography.**
Larina IV, Sudheendran N, Ghosn M, Jiang J, Cable A, Larin KV, Dickinson ME.
sJ Biomed Opt. 2008 Nov-Dec;13(6):060506. doi: 10.1117/1.3046716.
- 67. Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.**
Farhat FS, Kattan J, Chahine GY, Younes FC, Nasr FL, Mroue RM, Ghosn M.
Med Oncol. 2010 Sep;27(3):722-7. doi: 10.1007/s12032-009-9275-z. Epub 2009 Jul 31.
- 68. Acute myeloid leukemia and Langerhans' cell histiocytosis: multiple theories for an unusual presentation.**
Ghosn M, Haddad AC, Nassar MN, Abadjian GA, El Karak FR, Aftimos PG.
Leuk Res. 2010 Mar;34(3):406-8. doi: 10.1016/j.leukres.2009.07.025. Epub 2009 Aug 11.
- 69. Effect of temperature on permeation of low-density lipoprotein particles through human carotid artery tissues.**
Ghosn M, Leba M, Vijayananda A, Rezaee P, Morrisett JD, Larin KV.
J Biophotonics. 2009 Oct;2(10):573-80. doi: 10.1002/jbio.200810071.
- 70. Monitoring of glucose permeability in monkey skin in vivo using Optical Coherence Tomography.**
Ghosn M, Sudheendran N, Wendt M, Glasser A, Tuchin VV, Larin KV.
J Biophotonics. 2010 Jan;3(1-2):25-33. doi: 10.1002/jbio.200910075.
- 71. Chiral amplification with a stereodynamic triaryl probe: assignment of the absolute configuration and enantiomeric excess of amino alcohols.**
Ghosn M, Wolf C.
J Am Chem Soc. 2009 Nov 18;131(45):16360-1. doi: 10.1021/ja907741v.
- 72. ASSESSMENT OF TISSUE OPTICAL CLEARING AS A FUNCTION OF GLUCOSE CONCENTRATION USING OPTICAL COHERENCE TOMOGRAPHY.**
Sudheendran N, Mohamed M, Ghosn M, Tuchin VV, Larin KV.
J Innov Opt Health Sci. 2010;3(3):169-176.
- 73. Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.**
Farhat FS, Kattan J, Ghosn M.
Expert Rev Anticancer Ther. 2010 Apr;10(4):541-8. doi: 10.1586/era.09.179. Review.
- 74. Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience.**
Aftimos PG, Nasr EA, Nasr DI, Noun RJ, Nasr FL, Ghosn M, El Helou JA, Chahine GY.
Radiat Oncol. 2010 Jun 4;5:50. doi: 10.1186/1748-717X-5-50.

- 75. Stereocontrolled photodimerization with congested 1,8-bis(4'-anilino)naphthalene templates.**
Ghosn M, Wolf C.
J Org Chem. 2010 Oct 1;75(19):6653-9. doi: 10.1021/jo101547w.
- 76. A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.**
Ghosn M, Aftimos P, Farhat FS, Kattan JG, Hanna C, Haddad N, Nasr F, Chahine G.
Med Oncol. 2011 Dec;28 Suppl 1:S142-51. doi: 10.1007/s12032-010-9754-2. Epub 2010 Dec 7.
- 77. Experience with palliative care in patients with advanced cancer at a tertiary care hospital in a developing country.**
Ghosn M, Boutros C, Geara S, Kattan J, Nasr F, Chahine G.
Support Care Cancer. 2011 Apr;19(4):573-5. doi: 10.1007/s00520-010-1056-x. Epub 2010 Dec 18.
- 78. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.**
Larkin JM, Fisher RA, Pickering LM, Sohaib SA, Ghosn M, Christmas T, Cordiner RL, Gore ME.
J Clin Oncol. 2011 Mar 20;29(9):e241-2. doi: 10.1200/JCO.2010.33.4375. Epub 2011 Jan 18.
- 79. Time dependent changes in aortic tissue during cold storage in physiological solution.**
Ghosn M, Mashiatulla M, Mohamed MA, Syed S, Castro-Chavez F, Morrisett JD, Larin KV.
Biochim Biophys Acta. 2011 May;1810(5):555-60. doi: 10.1016/j.bbagen.2011.02.003. Epub 2011 Feb 21.
- 80. Synthesis, conformational stability, and asymmetric transformation of atropisomeric 1,8-bisphenolnaphthalenes.**
Ghosn M, Wolf C.
J Org Chem. 2011 May 20;76(10):3888-97. doi: 10.1021/jo200309g. Epub 2011 Apr 8.
- 81. Permeation of human plasma lipoproteins in human carotid endarterectomy tissues: measurement by optical coherence tomography.**
Ghosn M, Mashiatulla M, Syed SH, Mohamed MA, Larin KV, Morrisett JD.
J Lipid Res. 2011 Jul;52(7):1429-34. doi: 10.1194/jlr.D015255. Epub 2011 Apr 20.
- 82. Modification and implementation of NCCN guidelines on prostate cancer in the Middle East and North Africa region.**
Hassen WA, Karsan FA, Abbas F, Beduk Y, El-Khodary A, Ghosn M, Khader J, Khauli R, Rabah DM, Shamseddine A, Srinivas S; MENA Prostate Cancer Regional Guidelines Committee.
J Natl Compr Canc Netw. 2010 Jul;8 Suppl 3:S26-8.
- 83. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.**
Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirota N, Bodrogi I; REACT Study Group.
Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.
- 84. Adjuvant trastuzumab in HER2-positive breast cancer.**
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group.
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
- 85. Triple-negative breast cancer in Lebanon: a case series.**
Ghosn M, Hajj C, Kattan J, Farhat F, El Karak F, Nasr F, Abadjian G, Chahine G.
Oncologist. 2011;16(11):1552-6. doi: 10.1634/theoncologist.2011-0088. Epub 2011 Oct 21.

- 86. Chemoradiotherapy in early stage Hodgkin's lymphoma.**
Farha G, Nasr E, **Ghosn M**, Nasr DN, Nasr F, Kattan J, Azoury F, Aftimos P, Chahine G.
J Med Liban. 2011 Jul-Sep;59(3):122-5. French.
- 87. Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.**
Ghosn M, Saroufim A, Kattan J, Chahine G, Nasr F, Farhat F.
Med Oncol. 2012 Dec;29(4):2831-7. doi: 10.1007/s12032-012-0197-9. Epub 2012 Mar 4.
- 88. Sequential therapy with gemcitabine and Carboplatin followed by Paclitaxel as first line treatment for advanced urothelial cancer.**
Kattan JG, Boutros CY, Farhat FS, Chahine GY, Musallam KM, **Ghosn M**.
J Cancer. 2012;3:362-8. doi: 10.7150/jca.4224. Epub 2012 Sep 6.
- 89. A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses.**
Otrock ZK, Saab J, Aftimos G, Nasr F, Farhat FS, Khairallah S, Abadjian G, **Ghosn M**, Sidani H, Ibrahim A, Tawil A, Ghorra C, Meguerian Z, Mokaddem W, Dayeh W, Salem Z, Chahine G, Bitar N, Mugharbel A, Makdessi J, Khater C, El Hajj M, Abi Gerges D, Sfeir C, Kattan J, Ibrahim K, Saade M, Sadek H, Mahfouz RA, Kharfan-Dabaja MA, Zaatari G, Bazarbachi A.
Pathol Oncol Res. 2013 Oct;19(4):715-22. doi: 10.1007/s12253-013-9634-0. Epub 2013 May 8.
- 90. High-fat feeding-induced hyperinsulinemia increases cardiac glucose uptake and mitochondrial function despite peripheral insulin resistance.**
Gupte AA, Minze LJ, Reyes M, Ren Y, Wang X, Brunner G, **Ghosn M**, Cordero-Reyes AM, Ding K, Pratico D, Morrisett J, Shi ZZ, Hamilton DJ, Lyon CJ, Hsueh WA.
Endocrinology. 2013 Aug;154(8):2650-62. doi: 10.1210/en.2012-2272. Epub 2013 May 24.
- 91. Education and Imaging. Hepatobiliary and pancreatic: peliosis hepatis associated with multiple myeloma.**
Slim R, Hachem N, Smayra V, Yaghi C, Daniel F, Boujaoude J, Honein K, Sayegh R, **Ghosn M**.
J Gastroenterol Hepatol. 2014 Jan;29(1):5. doi: 10.1111/jgh.12469.
- 92. Ghosn M, Kourie HR, El Karak F, Hanna C, Antoun J, Nasr D.**
World J Gastroenterol. 2014 Mar 7;20(9):2352-7. doi: 10.3748/wjg.v20.i9.2352. Review.
- 93. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature.**
Abdayem P, **Ghosn M**, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK.
J Cancer. 2014 Mar 29;5(5):351-9. doi: 10.7150/jca.8304. eCollection 2014.
- 94. Successful treatment of Evans syndrome with Tacrolimus.**
Tabchi S, Hanna C, Kourie HR, Aftimos P, El Osta L, **Ghosn M**.
Invest New Drugs. 2015 Feb;33(1):254-6. doi: 10.1007/s10637-014-0155-9. Epub 2014 Sep 12.
- 95. Regorafenib: start low and go slow.**
Tabchi S, **Ghosn M**.
Target Oncol. 2015 Sep;10(3):445-7. doi: 10.1007/s11523-014-0352-7. Epub 2014 Dec 30.
- 96. Important advances in technology and unique applications related to cardiac magnetic resonance imaging.**
Ghosn M, Shah DJ.
Methodist DeBakey Cardiovasc J. 2014 Jul-Sep;10(3):159-62. doi: 10.14797/mdcj-10-3-159. Review.

- 97. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.**
Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, **Ghosn M**, Mehta A, Packman S, Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Shankar S, Solano MH, Ross L, Angell J, Peterschmitt MJ.
JAMA. 2015 Feb 17;313(7):695-706. doi: 10.1001/jama.2015.459.
- 98. Anal cancer treatment: current status and future perspectives.**
Ghosn M, Kourie HR, Abdayem P, Antoun J, Nasr D.
World J Gastroenterol. 2015 Feb 28;21(8):2294-302. doi: 10.3748/wjg.v21.i8.2294. Review.
- 99. Optimum chemotherapy for the management of advanced biliary tract cancer.**
Ghosn M, Kourie HR, El Rassy E, Chebib R, El Karak F, Hanna C, Nasr D.
World J Gastroenterol. 2015 Apr 14;21(14):4121-5. doi: 10.3748/wjg.v21.i14.4121. Review.
- 100. Distribution of testicular tumors in Lebanon: a single institution overview.**
Assi T, Rassy M, Nassereddine H, Sader-Ghorra C, Abadjian G, **Ghosn M**, Kattan J.
Asian Pac J Cancer Prev. 2015;16(8):3443-6.
- 101. Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer.**
Farhat FS, **Ghosn M**, Kattan JG.
Cancer Chemother Pharmacol. 2015 Aug;76(2):235-42. doi: 10.1007/s00280-015-2785-9. Epub 2015 May 30.
- 102. Gastrointestinal cancers in the era of theranostics: Updates and future perspectives.**
Ghosn M, Kourie HR, Tabchi S.
World J Gastroenterol. 2015 Jul 28;21(28):8473-7. doi: 10.3748/wjg.v21.i28.8473. Review.
- 103. Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement.**
Zekri J, Dreosti LM, **Ghosn M**, Hamada E, Jaloudi M, Khorshid O, Larbaoui B.
J Multidiscip Healthc. 2015 Jul 27;8:335-44. doi: 10.2147/JMDH.S85538. eCollection 2015. Review.
- 104. EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience.**
Naderi S, Ghorra C, Haddad F, Kourie HR, Rassy M, El Karak F, **Ghosn M**, Abadjian G, Kattan J.
Cancer Epidemiol. 2015 Dec;39(6):1099-102. doi: 10.1016/j.canep.2015.08.016. Epub 2015 Sep 9.
- 105. Treatment of cancer patients in their last month of life: aimless chemotherapy.**
Assi T, El Rassy E, Tabchi S, Ibrahim T, Moussa T, Chebib R, El Karak F, Farhat F, Chahine G, Nasr F, **Ghosn M**, Kattan J.
Support Care Cancer. 2016 Apr;24(4):1603-8. doi: 10.1007/s00520-015-2959-3. Epub 2015 Sep 21.
- 106. Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient.**
Ghosn M, Dagher A, El-Karak F.
J Biomed Res. 2015 Sep;29(5):420-2. doi: 10.7555/JBR.28.20130148. Epub 2014 Mar 30.
- 107. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.**
Park YS, Ji J, Zalberg JR, El-Serafi M, Buzaid A, **Ghosn M**.
Asia Pac J Clin Oncol. 2015 Dec;11(4):334-42. doi: 10.1111/ajco.12409. Epub 2015 Oct 15.

- 108. Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).**
Bekdash A, Darwish M, Timsah Z, Kassab E, Ghanem H, Najjar V, Ghosn M, Nasser S, El-Hajj H, Bazerbachi A, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ.
Transl Oncol. 2015 Oct;8(5):347-57. doi: 10.1016/j.tranon.2015.07.001.
- 109. Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow".**
Tabchi S, Ghosn M.
Target Oncol. 2016 Feb;11(1):127-8. doi: 10.1007/s11523-015-0406-5.
- 110. Validation of the EORTC QLQ-INFO 25 questionnaire in Lebanese cancer patients: Is ignorance a Bliss?**
Tabchi S, El Rassy E, Khazaka A, El Karak F, Kourie HR, Chebib R, Assi T, Ghor M, Naamani L, Richa S, Ghosn M, Kattan J.
Qual Life Res. 2016 Jun;25(6):1597-604. doi: 10.1007/s11136-015-1201-6. Epub 2015 Dec 10.
- 111. Watch and Wait in Lebanese Chronic Lymphocytic Leukemia Patients: How Relevant is it?**
Lutfallah AA, Kourie HR, Eid R, Farhat F, Ghosn M, Kattan J.
Asian Pac J Cancer Prev. 2016;17(1):215-7.
- 112. Is metastatic pancreatic cancer an untargetable malignancy?**
Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M.
World J Gastrointest Oncol. 2016 Mar 15;8(3):297-304. doi: 10.4251/wjgo.v8.i3.297. Review.
- 113. Metastatic gastric cancer treatment: Second line and beyond.**
Ghosn M, Tabchi S, Kourie HR, Tehfe M.
World J Gastroenterol. 2016 Mar 21;22(11):3069-77. doi: 10.3748/wjg.v22.i11.3069. Review.
- 114. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.**
Farhat F, Kattan JG, Ghosn M.
Cancer Chemother Pharmacol. 2016 May;77(5):1069-77. doi: 10.1007/s00280-016-3027-5. Epub 2016 Apr 8.
- 115. Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.**
Kattan J, Bachour M, Farhat F, El Rassy E, Assi T, Ghosn M.
Invest New Drugs. 2016 Aug;34(4):474-80. doi: 10.1007/s10637-016-0357-4. Epub 2016 May 10.
- 116. Informational Needs of Women with Breast Cancer Treated with Chemotherapy.**
Abi Nader E, Kourie HR, Ghosn M, Karak FE, Kattan J, Chahine G, Nasr F.
Asian Pac J Cancer Prev. 2016;17(4):1797-800.
- 117. Detection of LA and LAA Thrombus by CMR in Patients Referred for Pulmonary Vein Isolation.**
Kitkungvan D, Nabi F, Ghosn M, Dave AS, Quinones M, Zoghbi WA, Valderrabano M, Shah DJ.
JACC Cardiovasc Imaging. 2016 Jul;9(7):809-818. doi: 10.1016/j.jcmg.2015.11.029. Epub 2016 May 25.
- 118. Bilateral Choroidal Metastases from Prostate Cancer revealed in a patient under Abiraterone - Fourteen years after diagnosis.**
Kourie HR, Antoun J, Bteich F, Jalkh A, Ghosn M.
Gulf J Oncolog. 2016 May;1(21):67-9.
- 119. Road map for pain management in pancreatic cancer: A review.**
Lahoud MJ, Kourie HR, Antoun J, El Osta L, Ghosn M.

World J Gastrointest Oncol. 2016 Aug 15;8(8):599-606. doi: 10.4251/wjgo.v8.i8.599. Review.

120. Mesotheliomas in Lebanon: Witnessing a Change in Epidemiology.

Kattan J, Eid R, Kourie HR, Farhat F, Ghosn M, Ghorra C, Tomb R.
Asian Pac J Cancer Prev. 2016;17(8):4169-73.

121. The role of palliative care in the last month of life in elderly cancer patients.

Assi T, El Rassy E, Ibrahim T, Moussa T, Tohme A, El Karak F, Farhat F, Faddoul S, Ghosn M, Kattan J.
Support Care Cancer. 2017 Feb;25(2):599-605. doi: 10.1007/s00520-016-3444-3. Epub 2016 Oct 13.

122. Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature.

Ghosn M, Kourie HR, El Rassy E, Haddad FG, Hanna C, El Karak F, Nasr D.
World J Gastrointest Oncol. 2016 Oct 15;8(10):745-750. Review.

123. Abridged geriatric assessment is a better predictor of overall survival than the Karnofsky Performance Scale and Physical Performance Test in elderly patients with cancer.

Ghosn M, Ibrahim T, El Rassy E, Nassani N, Ghanem S, Assi T.
J Geriatr Oncol. 2017 Mar;8(2):128-132. doi: 10.1016/j.jgo.2016.11.002. Epub 2016 Dec 8.

124. Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience.

Assi T, El Rassy E, Khazzaka A, Moussa T, Ibrahim T, Kattan C, El Karak F, Farhat F, Ghosn M, Kattan J.
J Gastrointest Cancer. 2018 Mar;49(1):21-24. doi: 10.1007/s12029-016-9903-8.

125. Immune checkpoint inhibitors renal side effects and management.

Rassy EE, Kourie HR, Rizkallah J, Karak FE, Hanna C, Chelala DN, Ghosn M.
Immunotherapy. 2016 Dec;8(12):1417-1425. doi: 10.2217/imt-2016-0099. Review.

126. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.

Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J.
World J Gastroenterol. 2016 Dec 14;22(46):10124-10130. doi: 10.3748/wjg.v22.i46.10124. Review.

127. Lateralization index but not contralateral suppression at adrenal vein sampling predicts improvement in blood pressure after adrenalectomy for primary aldosteronism.

Tagawa M, Ghosn M, Wachtel H, Fraker D, Townsend RR, Trerotola S, Cohen DL.
J Hum Hypertens. 2017 Jul;31(7):444-449. doi: 10.1038/jhh.2016.92. Epub 2017 Jan 12.

128. PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma.

El Karak F, Bou-Orm IR, Ghosn M, Kattan J, Farhat F, Ibrahim T, Jreige M, El Cheikh J, Haidar M.
PLoS One. 2017 Jan 18;12(1):e0170299. doi: 10.1371/journal.pone.0170299. eCollection 2017.

129. An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.

Ghosn M, Assi T, El Rassy E, Moussa T, Kattan J.
Bull Cancer. 2017 Apr;104(4):385-387. doi: 10.1016/j.bulcan.2016.12.006. Epub 2017 Jan 26.

130. Unusual Destruction of the Nasal Septum.

Assi T, El Rassy E, Moussa T, Tabchi S, Chebib R, Ghosn M.
Gulf J Oncolog. 2016 Sep;1(22):61-63.

131. Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.

El Rassy E, Assi T, El Karak F, **Ghosn M**, Kattan J.

Clin Res Hepatol Gastroenterol. 2017 Mar;41(2):e26-e28. doi: 10.1016/j.clinre.2016.11.012. Epub 2017 Feb 17.

132. New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy .

Ghosn M, Palmer MB, Najem CE, Haddad D, Merkel PA, Hogan JJ.

Clin Nephrol. 2017 May;87 (2017)(5):261-266. doi: 10.5414/CN109019.

133. Immunotherapies in sarcoma: Updates and future perspectives.

Ghosn M, El Rassy E, Kourie HR.

World J Clin Oncol. 2017 Apr 10;8(2):145-150. doi: 10.5306/wjco.v8.i2.145. Review.

134. Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.

Kourie HR, Tabchi S, **Ghosn M**.

World J Gastroenterol. 2017 May 7;23(17):3017-3021. doi: 10.3748/wjg.v23.i17.3017.

135. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim SW, **Ghosn M**, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A.

J Thorac Oncol. 2017 Sep;12(9):1357-1367. doi: 10.1016/j.jtho.2017.07.005. Epub 2017 Jul 17.

136. Left ventricular function in patients with hypertrophic cardiomyopathy and its relation to myocardial fibrosis and exercise tolerance.

Maragiannis D, Alvarez PA, **Ghosn M**, Chin K, Hinojosa JJ, Buergler JM, Shah DJ, Nagueh SF.

Int J Cardiovasc Imaging. 2018 Jan;34(1):121-129. doi: 10.1007/s10554-017-1214-z. Epub 2017 Jul 26.

137. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.

Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris H, **Ghosn M**, Mehta A, Packman S, Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Gaemers SJM, Tayag R, Peterschmitt MJ.

Am J Hematol. 2017 Nov;92(11):1170-1176. doi: 10.1002/ajh.24877. Epub 2017 Oct 3.

138. Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning.

Tawil MH, El Khoury R, Tomb R, **Ghosn M**.

Int J Trichology. 2017 Apr-Jun;9(2):87-89. doi: 10.4103/ijt.ijt_1_17.

139. The Therapeutic use of human albumin in cancer patients' management.

Moujaess E, Fakhoury M, Assi T, Elias H, El Karak F, **Ghosn M**, Kattan J.

Crit Rev Oncol Hematol. 2017 Dec;120:203-209. doi: 10.1016/j.critrevonc.2017.11.008. Epub 2017 Nov 20. Review.

140. International Medical Graduates in Nephrology: Roles, Rules, and Future Risks.

Berns JS, **Ghosn M**, Altamirano RR.

Am J Kidney Dis. 2018 Jul;72(1):113-117. doi: 10.1053/j.ajkd.2017.09.016. Epub 2017 Dec 6.

141. Where do the immune checkpoint inhibitors stand in the management of triple negative breast cancer?

Rassy EE, Karak FE, **Ghosn M**.

Immunotherapy. 2018 Feb 1;10(4):247-250. doi: 10.2217/imt-2017-0171.

142. Triple negative breast cancer: are we scoring a home run?

El Rassy E, Ibrahim N, **Ghosn M**.

Future Oncol. 2018 Apr;14(9):793-796. doi: 10.2217/fon-2017-0656. Epub 2018 Mar 12.

- 143. Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma.**
Hanna C, Villa D, Irani C, **Ghosn M**, El Rassy E.
Clin Lymphoma Myeloma Leuk. 2018 May;18(5):e197-e200. doi: 10.1016/j.clml.2018.03.008. Epub 2018 Mar 19.
- 144. Oral health and chemotherapy act as cofactors in malnutrition in the elderly with other cancers than head and neck malignancies.**
El Osta N, El Osta L, Lassauzay C, **Ghosn M**, Tubert-Jeannin S, Hennequin M.
Clin Oral Investig. 2019 Jan;23(1):235-243. doi: 10.1007/s00784-018-2430-1. Epub 2018 Apr 2.
- 145. Evaluation of chronic kidney disease in cancer patients: is there a preferred estimation formula?**
Sleilalty G, El Rassy E, Assi T, Al Rassy N, Naseh J, Rizkallah J, Finianos S, Azar H, Chelala DN, El Karak F, Kattan J, **Ghosn M**.
Intern Med J. 2018 Nov;48(11):1382-1388. doi: 10.1111/imj.13933.
- 146. Lethal hepatotoxicity following 5-fluorouracil/cisplatin chemotherapy: a relevant case report.**
Hajj A, **Ghosn M**, Mourad D, Hojaiban K, Mousallem P, Khabbaz LR.
Per Med. 2017 May;14(3):197-201. doi: 10.2217/pme-2016-0085. Epub 2017 May 5.
- 147. Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience.**
El Rassy E, **Ghosn M**, Farhat F, Bakouny Z, Assi T, Chahine G, Nasr F, Haddad FG, El Karak F, Kattan J.
Breast Care (Basel). 2018 Apr;13(2):121-125. doi: 10.1159/000481339. Epub 2018 Jan 31.
- 148. Do immune checkpoint inhibitors perform identically in patients with weight extremes?**
Rassy EE, **Ghosn M**, Rassy NA, Assi T, Robert C.
Immunotherapy. 2018 Jul;10(9):733-736. doi: 10.2217/imt-2018-0053.
- 149. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).**
Carles J, Pichler A, Korunkova H, Tomova A, **Ghosn M**, El Karak F, Makdessi J, Koroleva I, Barnes G, Bury D, Özatilgan A, Hitier S, Katolicka J.
BJU Int. 2019 Mar;123(3):456-464. doi: 10.1111/bju.14509. Epub 2018 Sep 16.
- 150. Prognostic and predictive biomarkers in nonmetastatic colorectal cancers.**
Haddad FG, Eid R, Kourie HR, Barouky E, **Ghosn M**.
Future Oncol. 2018 Sep;14(21):2097-2102. doi: 10.2217/fon-2017-0708. Epub 2018 Aug 13. Review.
- 151. Four-dimensional flow cardiovascular magnetic resonance in aortic dissection: Assessment in an ex vivo model and preliminary clinical experience.**
de Beaufort HW, Shah DJ, Patel AP, Jackson MS, Spinelli D, Yang EY, Ghosn MG, Autry K, Igo SR, Lumsden AB, Little SH, Trimarchi S, Bismuth J.
J Thorac Cardiovasc Surg. 2019 Feb;157(2):467-476.e1. doi: 10.1016/j.jtcvs.2018.06.022. Epub 2018 Jul 3.
- 152. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.**
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators.
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.

153. The nephrotoxicity of immune checkpoint inhibitor-based combinations.

El Rassy E, Bakouny Z, Yared F, Chelala DN, El Karak F, **Ghosn M**.
Eur J Cancer. 2018 Nov;103:274-278. doi: 10.1016/j.ejca.2018.07.126. Epub 2018 Sep 6.

154. Real-life single institutional experience.

Assi T, Kattan J, El Rassy E, Tabchi S, Chebib R, Moussa T, Hanna C, El Karak F, Farhat F, **Ghosn M**.
J Cancer Res Ther. 2018 Jul-Sep;14(5):1112-1116. doi: 10.4103/0973-1482.183552.

155. Causes of death in older patients with cancer: Experience of a tertiary care center in Lebanon.

Assi T, Bakouny Z, Labaki C, El Rassy E, Khazzaka A, Jabbour R, Haddad FG, Tohme A, El Karak F, **Ghosn M**, Kattan J.
J Geriatr Oncol. 2019 Mar;10(2):365-367. doi: 10.1016/j.jgo.2018.10.017. Epub 2018 Oct 31.

156. Is there a role for the platelet-to-lymphocyte ratio in chronic lymphocytic leukemia?

Bakouny Z, Rassy EE, Yared F, Lutfallah AA, **Ghosn M**, Farhat F, Kattan J.
Future Sci OA. 2018 Oct 5;4(10):FSO344. doi: 10.4155/fsoa-2018-0061. eCollection 2018 Dec.

157. Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

El Rassy E, Assi T, Bakouny Z, El Karak F, Pavlidis N, **Ghosn M**.
Future Oncol. 2019 Mar;15(8):909-923. doi: 10.2217/fon-2018-0663. Epub 2019 Jan 23. Review.

158. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).

Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vázquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E; PRINCIPAL Study Group.
Oncologist. 2019 Apr;24(4):491-497. doi: 10.1634/theoncologist.2018-0787. Epub 2019 Mar 13.

159. Lung cancer and immunotherapy: a real-life experience from second line and beyond.

El Karak F, Haddad FG, Eid R, Al Ghor M, El Rassy E, Ahmadieh N, Choullamy T, Halim NA, Tfiayli A, Farhat F, Kattan J, Nasr F, **Ghosn M**, Assi HI.
Future Oncol. 2019 Aug 19. doi: 10.2217/fon-2019-0144. [Epub ahead of print]

Chapters in Books

1. ROUGIER Ph, LASSER P, DROZ J.P, ELIAS D, **GHOSN M**, DUCREUX M, LUMBROSO J, SIDIBE S. Which intra-arterial hepatic chemotherapy for liver metastasis from colorectal carcinoma. Dans: Kreidler, Link, Aigner, eds. Advances in Regional Cancer Therapy, 1988: 92 -9.
2. **GHOSN M**, DROZ J.P, HAYAT M. Plant Alkaloids-Etoposide. In: DROZ J.P., CVITKOVIC E., ARMAND J.P., KHOURY S, eds. Handbook of chemotherapy in Clinical Oncology, 1988: 150 – 2.
3. DROZ J.P, AZAB M, **GHOSN M**, COURT B.H, PERRIN J.L, TRAVALGI J.P, WIBAULT P. Pilot phase II trial of pre and post operative Cisplatin, Methotrexate and Vinblastin in infiltrating bladder cancer. In: JACQUILLAT Claude WEIL Marise, KHAYAT David, co-Eds. Neo Adjuvant Chemotherapy II, London-Paris: INSERM, 1988: 405 – 9.
4. DROZ J.P., LUPERA H., **GHOSN M**, CHARROT P., METZ R., FARGEOT P., THEODORE C, ALLAIN Y. Phase II trial with Methotrexate, Vinblastin, Adriamycin and Cisplatin (M-VAC Regimen) in advanced stage bladder cancer. In: A. ýSTEG- F. DI SILVERIO, eds. New trends in bladder cancer chemotherapy. International Workshop in Urology Proceedings Acta Medica, Roma, 1989: 53 – 6.

5. DROZ J.P, THEODORE C, **GHOSN M.** AZAB M, OSTRONOFF, LUPERA H, COURT B.H, PERRIN J.L. Current status of phase II trials of new drugs in advanced urothelial tract cancers. In: A. STEG, F. DI SILVERIO Eds. New trends in bladder cancer chemotherapy International Workshop in Urology Proceedings, Acta Medica, Roma 1989: 9 – 11.
6. DROZ J.P, RIBRAG V, **GHOSN M.** GUIMARES J, THEODORE C, AZAB M, OSTRONOFF M, MAHJOUBI M, MORAN A, PICO J, BOUTAN LAROZE A, HAYAT M. Phase II trial with Etoposide (VP16) plus Ifosfamide plus high dose Cisplatin (VIhP regimen) in refractory germ cell tumors. In: Gerald P. MURPHY, Saad KHOURY, Alan R. Liss, Eds. Therapeutic Progress in Urological Cancers, New York, 1989: 739 – 47.
7. DROZ J.P, **GHOSN M.** THEODORE C. Chimiothérapie Cancers Uro-Génitaux. In: Adolphe Steg & François Eschwege Eds, Flammarion and Cie editors, France, 1991: 474 – 87.
8. DROZ J.P, REY A, MAHJOUBI M, KRAMAR A, BOULEUC C, **GHOSN M.** AZAB M, DE FORGES A. Prognostic factors for survival in adult patients with metastatic renal cell carcinoma: a multivariate analysis in New trends in the diagnosis and treatment of renal cancer. Dans: Edizioni e Congressi. Acta Medica, Roma, 1991: 13 – 20.
9. DROZ J.P, **GHOSN M.** Salvage chemotherapy in non seminomatous germ cell tumors: How far can we go?. In: A John Wiley & Sons, Inc., Publication, New York, 1992.
10. CVITKOVIC E, DROZ J.P, KATTAN J, **GHOSN M.** Cisplatin. In: Handbook of chemotherapy in Clinical Oncology, Second Edition, Scientific Communication International Ltd, 1993.
11. DROZ J.P, CVITKOVIC E, KATTAN J, **GHOSN M.** Carboplatin. In: Handbook of chemotherapy in Clinical Oncology, Second Edition, Scientific Communication International Ltd, 1993.
12. **GHOSN M.** Inflammatory breast cancer in the Arab World. In: Euro Cancer 2010, Edited by Michel Boiron, Michel Marty. John Libey Ltd, 2010: 173-174.
13. **GHOSN M.**, HANNA C., EL.KARAK F., “Multi-Disciplinary Management of Metastatic Pancreatic Cancer” in: Pancreatic cancer, Clinical Management, First Edition, Edited by Sanjay K.Srivastava, March 2012:197-204.
14. KOURIE H., ABADJIAN G., GHORRA C., GERMANOS M., **GHOSN M.**, « Epidemiologie des cancers des adolescents et jeunes adultes au Liban » in : Euro Cancer, Societe francaise du cancer, Edited by Michel Boiron, Michel Marty. John Libey Ltd, 2012: 161-164.